Moncton, Canada Clinical Trials

A listing of Moncton, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 19 clinical trials
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

Centre Hospitalier Universitaire Dr-Georges-L.-Dumont
 (0.7 away) Contact site
  • 2496 views
  • 22 Jul, 2021
  • +209 other locations
Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS).

evobrutinib
teriflunomide
aubagio
Research Site 128
 (0.4 away) Contact site
  • 0 views
  • 21 Jul, 2021
  • +261 other locations
Efficacy and Safety of Olaparib Olaparib + Bevacizumab Compared to Bevacizumab + 5-Fluorouracil (FU)

This is an efficacy and safety study of olaparib alone or in combination with bevacizumab being compared to bevacizumab with Fluorouracil (5-FU) in participants with unresectable or metastatic colorectal cancer (CRC) who have not progressed following first-line induction of FOLFOX with bevacizumab. Hypothesis 1 - Olaparib + Bevacizumab is superior …

folfox regimen
bevacizumab
colorectal adenocarcinoma
adenocarcinoma
fluorouracil
Moncton Hospital - Horizon Health Network ( Site 0201)
 (1.8 away) Contact site
  • 10 views
  • 18 Jul, 2021
  • +122 other locations
Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A

The primary purpose of the study is to compare the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II -IIIA and the subset of IIIB (T>5cm N2 disease) completely resected (R0) non-small cell lung cancer (NSCLC).

lung carcinoma
systemic therapy
alopecia
Novartis Investigative Site
 (1.8 away) Contact site
  • 645 views
  • 15 Jul, 2021
  • +414 other locations
Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency

The primary objective of this study is to determine the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo in the treatment of participants in heart failure with a reduced ejection fraction and with iron deficiency

ejection fraction
bypass graft
iron
nesiritide
nt-probnp
Nova Scotia Health Authority
 (114.8 away) Contact site
  • 5316 views
  • 22 Jul, 2021
  • +365 other locations
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the participants get is decided by chance. …

body mass index
overweight or obesity
cardiovascular disease
Novo Nordisk Investigational Site
 (3.9 away) Contact site
  • 7712 views
  • 18 Jul, 2021
  • +1164 other locations
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with BCG, compared to BCG monotherapy, in participants with HR NMIBC that is either persistent or recurrent following adequate BCG induction (Cohort A), or that is nave to BCG treatment (Cohort B). The primary hypothesis …

Horizon Health Network ( Site 0160)
 (1.8 away) Contact site
  • 108 views
  • 23 Jul, 2021
  • +138 other locations
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with unresected stage I or IIA non-small cell lung cancer (NSCLC). The primary study hypotheses are: SBRT plus pembrolizumab prolongs Event-free Survival (EFS) compared …

lung carcinoma
mk-3475
pembrolizumab
stereotactic body radiation therapy
Moncton Hospital - Horizon Health Network ( Site 0105)
 (1.8 away) Contact site
  • 121 views
  • 21 Jul, 2021
  • +178 other locations
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

A global, randomized phase III study to evaluate perioperative pembrolizumab with radical cystectomy + pelvic lymph node dissection (RC+PLND) versus RC+PLND alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).

Moncton Hospital - Horizon Health Network ( Site 0112)
 (1.8 away) Contact site
  • 95 views
  • 22 Jul, 2021
  • +198 other locations
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable) Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-positive solid tumors.

mk-3475
pembrolizumab
advanced cancer
measurable disease
cancer
Moncton Hospital - Horizon Health Network ( Site 0206)
 (1.8 away) Contact site
  • 16 views
  • 16 Jul, 2021
  • +147 other locations